

medicina intensiva

http://www.medintensiva.org/en/



SCIENTIFIC LETTER

Analysis of energy load values in mechanical ventilation in obese patients with hypoxemic respiratory failure secondary to SARS-CoV-2

Análisis de los valores de carga de energía en ventilación mecánica en pacientes obesos con insuficiencia respiratoria hipoxémica secundaria a SARS-CoV2

When addressing the limitations raised by Rodríguez et al.¹ in their recent study published in *Medicina Intensiva*, it is highlighted that, due to the particularities of the database developed during the pandemic, records on relevant aspects of pulmonary mechanics that could be associated with the clinical outcomes of patients were not included. We agree with the authors that such characteristics of pulmonary mechanics in patients undergoing mechanical ventilation can vary significantly depending on the presence or absence of obesity.^{2,3}

Certainly, protective ventilation is based on the administration of tidal volume adjusted to the ideal body weight (IBW) as an essential part of its approach. However, estimating IBW poses significant challenges: for example, English origin of the formulas used, consistent with an old rule developed from height and weight tables lacks consideration of the patient's age, which can lead to inaccuracies when applied to populations different from those used in its formulation.⁴

To offer a more complete perspective in this regard and under the hypothesis that in obese patients undergoing mechanical ventilation, the energy load parameters will vary considerably from one individual to the next, as opposed to non-obese patients, and that this variability will be closely associated with the degree of hypoxemia experienced, we present our pulmonary mechanics data in patients with C-ARDS, categorized by degree of hypoxemia and obesity.

This is a retrospective, observational, and analytical cohort study of all cases hospitalized due to SARS-CoV-2 infection with ICU admission from March 2020 through March 2022. Data were obtained from the COVID-19 patient cohort registry of an intensive care unit in a tertiary referral center. The local Research Ethics Committee approved the study,

and informed consent (written and/or *via* phone call) was obtained from the patients/legal representatives.

During the analyzed period, a total of 911 patients were admitted to the ICU with SARS-CoV-2 disease. After excluding patients younger than 18 years, those who were ventilated in pressure-controlled mode, and those with defective or incomplete records, data analysis was conducted on a total of 253 patients.

Patients were categorized as severely hypoxemic or nonseverely hypoxemic based on the value of the arterial partial pressure of oxygen to the fraction of inspired oxygen (P/F) ratio at ICU admission. P/F values <150 mmHg were categorized as severely hypoxemic, while P/F values \geq 150 mmHg were categorized as non-severely hypoxemic. Based on body mass index (BMI), patients were categorized upon ICU admission as obese with BMI \geq 30 kg/m², or non-obese with BMI < 30 kg/m².⁵ For analysis, patients were categorized into 4 groups: group #1: patients without severe hypoxemia or obesity; group #2: patients with severe hypoxemia without obesity; group #3: patients without severe hypoxemia with obesity; group #4: patients with severe hypoxemia and obesity.

In calculating bioenergetic variables, Mechanical Power (MP) was defined based on Gattinoni's simplified formula, Driving Power as: $VT \times f \times [(Pplateau - PEEP)/2]$ and Dynamic Power as: $VT \times f \times [(Pplateau + PEEP)/2]$.^{3,6-8}

Inter-group comparisons of percentages were made using ANOVA, and continuous variables were compared using the Kruskal–Wallis test. A multivariate logistic regression analysis was used to explore the association of variables with the primary outcome: 28-day mortality, for each risk factor considered in 3 different models: MP Model, Driving Power Model, and Dynamic Power Model. To interpret the results in a valid clinical scenario, covariates that showed significant differences in the bivariate analysis or a trend (p < 0.2) without evidence of multicollinearity issues (assessed with a Variance Inflation Factor (VIF) <3) were included. The analyzed models are presented as odds ratios (OR) with their 95% confidence intervals (95%CI).

Group #4 (patients with severe hypoxia and obesity) had the highest average MP values: 20.96 J/min. No significant differences were found in the inter-group analysis. The highest mean Driving Power value was evidenced in group #4 (patients with severe hypoxia and obesity): 49.91 cm $H_2O \times L/min$; while the highest mean Dynamic Power value was observed in group #3 (patients without severe hypoxemia with obesity): 153.13 (129.75–185.95) cm $H_2O \times L/min$ (Table 1). Dynamic Power showed significant differences between patient groups, con-

DOI of original article: https://doi.org/10.1016/j.medin.2024. 06.004

Table 1	Clinica	l-epidemiologica	al characteristics	and mechanica	l ventilation data

	Group #1	Group #2	Group #3	Group #4	р
	n = 72	n = 133	n = 12	n = 36	
Age (years)	64 (56-70)	65.0	55 (48-72)	62 (51-68)	0.14
Median (p25-p75)		(59–73)			
Male sex n (%)	51 (71%)	98 (74%)	7 (58%)	23 (64%)	0.51
Co-morbidities					
BMI (kg/m ²)	26 (23-28)	27 (24-29)	47 (46-50)	48 (46-48)	<0.01
Median (p25-p75)					
Diabetic, n (%)	13 (18%)	30 (22.5%)	4 (33.3%)	9 (25%)	0.62
Dyslipidemia, n (%)	20 (27.7%)	36 (27.0%)	3 (25%)	16 (44.4%)	0.21
Smoker, n (%)	23 (31.9%)	50 (37.6%)	4 (33.3%)	13 (36.1%)	0.87
P/F at ICU admission (mmHg)	180	110	184	115	<0.01
Median (p25-p75)	(165–211)	(91–130)	(164-202)	(99–136)	
Ventilatory variables					
VT (mL) ^a	470	460	480	460	0.33
Median (p25-p75)	(450-480)	(440-490)	(467-485)	(435-480)	
Respiratory rate (resp/min)	18 (16-18)	18 (16–18)	18 (17-20)	18 (17-20)	0.02
Median (p25-p75)					
Peak pressure (cm H ₂ O)	31 (30-33)	31 (28-33)	31 (29-32)	32 (30-33)	0.78
Median (p25-p75)					
PEEP (cm H ₂ O)	10 (8-12)	12 (10–12)	12 (9–14)	12 (10-14)	0.22
Median (p25-p75)					
Plateau pressure (cm H ₂ O)	22 (20-26)	22 (20-25)	24.5	23.5	0.73
Median (p25-p75)			(20-26)	(20-25)	
Compliance (mL/cm H ₂ O)	41.3 (33.7-50.5)	41.5 (33.3-55.1)	48.0 (33.7-57.8)	43.6 (33.5-50.0)	0.83
Median (p25-p75)					
Driving pressure (cm H ₂ O)	11 (9–14)	11 (8-14)	10 (8-14)	11.5	0.87
Median (p25-p75)				(9-13)	
Mechanical Power (J/min)	19 (17-22)	20 (17-22)	20 (18-22)	21 (18-23)	0.40
Driving Power (cm $H_2O \times L/min$)	47 (35-55)	45 (32-57)	49 (35-63)	50 (39-58)	0.68
Dynamic Power (cm $H_2O \times L/min$)	131 (115–153)	135 (115–150)	153 (130–186)	149 (122-167)	0.07
Therapies used					
Previous HFNC use, n (%)	50 (69%)	54 (40%)	7 (58%)	19 (52%)	<0.01
Prophylactic anticoagulation, n (%)	52 (72%)	96 (72%)	9 (75%)	27 (75%)	0.98
Empirical antibiotic therapy, n (%)	61 (84%)	114 (86%)	10 (83%)	31 (86%)	0.95
Prone positioning therapy, n (%)	34 (47%)	71 (54%)	8 (66%)	20 (55%)	0.58
Remdesivir	5 (7%)	14 (10%)	2 (16%)	3 (8%)	0.69
Corticosteroid use, n (%)	59 (81.9%)	99 (74.4%)	9 (75%)	29 (80.5%)	0.62
Need for vasopressors/inotropes during	43 (60%)	73 (55%)	10 (83%)	17 (47%)	0.15
ICU stay, n (%)					
CRRT, n (%)	6 (8%)	6 (4%)	0 (-)	2 (5%)	0.81
ECMO support	1 (1%)	3 (2%)	0 (-)	0 (-)	0.75
Evolutionary variables					
Days on MV	8 (5-20)	10 (7-18)	13 (6-24)	9 (6-14)	0.41
Median (p25-p75)					
Tracheostomy, n (%)	14 (19%)	22 (16%)	3 (25%)	5 (14%)	0.78
ICU stay (days)	15 (8-24)	12 (9-25)	12 (8-25)	13 (9-19)	0.98
Median (p25-p75)					

Group #1: non-obese and non-hypoxemic patients; group #2: hypoxemic and non-obese patients; group #3: obese and non-hypoxemic patients; group #4: obese and hypoxemic patients. BMI, body mass index; CRRT, continuous renal replacement therapies; ECMO, extracorporeal membrane oxygenation; HFNC, high-flow nasal cannula; P/F, ratio of arterial partial pressure of oxygen to the fraction of inspired oxygen; PEEP, positive end-expiratory pressure; RR, respiratory rate; VT, tidal volume.

^a VT, tidal volume adjusted to ideal weight (6-8 mL/kg).

sidering the presence of the obesity variable in the group categorization.

In the logistic regression analysis performed (Table 2), in the 3 adjusted models, only age proved to be a statistically

significant independent predictor of mortality. Although body mass index (BMI) \geq 30 kg/m² showed a positive association with mortality, it did not reach statistical significance in any of the 3 adjusted models. Other factors such as the P/F

Table 2	Risk factors associated	l with the 28-da	y mortality rate t	hrough multivariable:	logistic regression	1 analysis.
---------	-------------------------	------------------	--------------------	-----------------------	---------------------	-------------

 Risk factors	OR	95%CI	D	VIF	
MP Model			F		
Age	1.05	1.01-1.09	0.01	1.09	
$BMI > 30 \text{ kg/m}^2$	1.55	0.62-3.86	0.34	1.05	
P/F at ICU admission (mmHg)	0.99	0.99-1.00	0.83	1.19	
Respiratory rate	1.04	0.85-1.27	0.63	1.47	
Prior HFNC use	0.97	0.44-2.11	0.93	1.18	
Need for vasopressors	1.07	0.49-2.31	0.85	1.11	
Mechanical Power (J/min)	0.96	0.87-1.06	0.46	1.44	
Driving Power Model					
Age	1.05	1.01-1.09	0.01	1.09	
$BMI \ge 30 \text{ kg/m}^2$	1.60	0.64-3.99	0.31	1.05	
P/F at ICU admission (mmHg)	0.99	0.99-1.00	0.80	1.19	
Respiratory rate	0.94	0.77-1.16	0.59	1.48	
Prior HFNC use	1.01	0.46-2.20	0.97	1.17	
Need for vasopressors	1.09	0.51-2.36	0.81	1.12	
Driving Power (cm $H_2O \times L/min$)	1.01	0.99-1.03	0.22	1.40	
Dynamic Power Model					
Age	1.05	1.01-1.09	0.00	1.10	
$BMI \ge 30 \text{ kg/m}^2$	1.47	0.58-3.70	0.40	1.05	
P/F at ICU admission (mmHg)	0.99	0.99-1.01	0.86	1.20	
Respiratory rate	0.94	0.77-1.15	0.56	1.59	
Prior HFNC use	1.05	0.48-2.30	0.89	1.16	
Need for vasopressors	1.03	0.47-2.22	0.93	1.09	
Dynamic Power (cm $H_2O \times L/min$)	1.02	0.99-1.02	0.19	1.61	

BMI, body mass index; P/F, ratio of arterial partial pressure of oxygen to the fraction of inspired oxygen.

Data expressed as odds ratios (OR) with their 95% confidence intervals (CI95%). The p-value was calculated using logistic regression analysis. The diagnosis of multicollinearity is shown with the Variance Inflation Factor (VIF).

ratio at ICU admission, respiratory rate, prior use of HFNC, and the need for vasopressors did not show a significant association with mortality in any of the models.

Our analysis proves that the parameterization of mechanical ventilation in obese patients during the SARS-CoV-2 pandemic led to a higher Dynamic Power than in the rest of the patients, without this finding conditioning an increase in MP or an effect on 28-day mortality at the ICU setting.

In this context, former studies have demonstrated that the overall compliance of the respiratory system decreases in obese patients due to a decrease in chest wall compliance, while lung compliance remains unchanged.⁹ Obese patients may require higher PEEP values during mechanical ventilation to counteract the weight load imposed on it. This situation requires a higher energy load: Dynamic Power. Various published studies on PEEP values used in these patients describe the need for a mean PEEP between 11 and $18 \text{ cm H}_2\text{O}$ to achieve total recruitment of collapsed lung tissue.⁸

Our analysis was unable to detect a statistically significant association between energy load variables and 28-day mortality in this patient cohort. Despite the theoretical relevance of these variables and their potential impact on clinical outcomes, our study may lack sufficient statistical power to detect this effect on short-term mortality.

The confirmation of these findings would raise questions about the clinical utility of these energy load measures in predicting outcomes in critically ill obese patients. It is possible that other factors, such as the severity of the underlying disease, response to treatment, and comorbidities, have a more significant impact on mortality than energy load measures *per se*.

Consequently, these findings highlight the need for additional research to better understand the relationship between energy load in mechanical ventilation and clinical outcomes, as well as to identify more predictive biomarkers and clinical variables of mortality in critically ill patients.¹⁰

Our results in patients with acute respiratory distress syndrome (ARDS) raise questions about their extrapolation to the "typical" ARDS population, especially in those with bacterial pneumonia and intra-abdominal disease. Understanding the unique viral pathogenesis of SARS-CoV-2 underlies in the physiological differentiation between C-ARDS and non-COVID-19-related ARDS. Proinflammatory responses, closely associated with pulmonary vascular endothelial injury and immunothrombosis, show significant discrepancies between both types of ARDS.¹¹

Authors' contributions

All the signatory authors met the authorship requirements and declared no conflicts of interest whatsoever.

Alejandro González-Castro: ideation, preparation, and drafting of the manuscript. Elena Cuenca Fito: data mining. Yhivian Peñasco: preparation, proofreading. Carmen Huertas: database cleaning. Aurio Fajardo: proofreading.

References

- Rodríguez A, Martín-Loeches I, Moreno G, Díaz E, Ferré C, Salgado M, et al. On behalf COVID-19/SEMCYUC Working Group. Association of obesity on the outcome of critically ill patients affected by COVID-19. Med Intensiva (Engl Ed). 2024;48:142–54, http://dx.doi.org/10.1016/j.medine.2023.08.003.
- Tocalini P, Vicente A, Amoza RL, García Reid C, Cura AJ, Tozzi WA, et al. Association between obesity and mortality in adult patients receiving invasive mechanical ventilation: a systematic review and meta-analysis. Med Intensiva (Engl Ed). 2020;44:18–26, http://dx.doi.org/10. 1016/j.medin.2018.07.006.
- Pelosi P, Croci M, Ravagnan I, Tredici S, Pedoto A, Lissoni A, et al. The effects of body mass on lung volumes, respiratory mechanics, and gas exchange during general anesthesia. Anesth Analg. 1998;87:654–60, http://dx.doi.org/10.1097/00000539-199809000-00031.
- Pai MP, Paloucek FP. The origin of the ''ideal'' body weight equations. Ann Pharmacother. 2000;34:1066-9, http://dx.doi.org/10.1345/aph.19381.
- Rivera-Fernández R, Díaz-Contreras R, Chavero-Magro MJ. Mortality and prognostic indexes in obese patients admitted to the intensive care unit. Med Intensiva. 2006;30:162–6, http://dx.doi.org/10.1016/s0210-5691(06)74497-7.
- Vasques F, Duscio E, Cipulli F, Romitti F, Quintel M, Gattinoni L. Determinants and prevention of ventilatorinduced lung injury. Crit Care Clin. 2018;34:343–56, http://dx.doi.org/10.1016/j.ccc.2018.03.004.
- Vargas M, Servillo G. Neuromuscular blocking agents for ARDS: firm evidence for ICU mortality but not for long-term mortality. Respir Care. 2021;66:887.2–8, http://dx.doi.org/10.4187/respcare.08926.
- 8. Syed MKH, Selickman J, Evans MD, Dries D, Marini JJ. Elastic power of mechanical ventilation in morbid obe-

Frailty, prevalence in our intensive care units and differential characteristics of these patients

Fragilidad, prevalencia en nuestras unidades de cuidados intensivos y características diferenciales de los pacientes frágiles

Clinical frailty is a syndrome characterized by a reduction in physical activity, physiological function, and cognitive reserve, with molecular and physiological characteristics including increased inflammatory markers.¹

The frail individual presents, in varying combinations, reduced mobility, loss of muscle mass, poor nutritional status, and a decreased cognitive function.² Each of these factors and their combination make the individual more susceptible to extrinsic stressors, resulting in higher all-cause mortality vs non-frail individuals of the same age range.³ Although frailty is more prevalent in older individuals (25% in those older than 65 years vs 50% in those older than 85 years),⁴ frailty and aging are not synonymous. Therefore,

sity and severe hypoxemia. Respir Care. 2021;66:626-34, http://dx.doi.org/10.4187/respcare.08234.

- 9. De Lucas Ramos P, Rodríguez González-Moro J, Rubio Socorro Y. Obesidad y función pulmonar. Arch Bronconeumol. 2004;40:27–31, http://dx.doi.org/10.1157/13077885.
- Bonatti G, Robba C, Ball L, Silva PL, Rocco PRM, Pelosi P. Controversies when using mechanical ventilation in obese patients with and without acute distress respiratory syndrome. Expert Rev Respir Med. 2019;13:471-9, http://dx.doi.org/10.1080/17476348.2019.1599285.
- Selickman J, Vrettou CS, Mentzelopoulos SD, Marini JJ. COVID-19-related ARDS: key mechanistic features and treatments. JCM. 2022;11:4896, http://dx.doi.org/10.3390/jcm11164896.

Alejandro González-Castro^{a,b,*}, Elena Cuenca Fito^a, Carmen Huertas Martín^a, Yhivian Peñasco^a, Aurio Fajardo Campoverdi^{b,c}

^a Servicio de Medicina Intensiva, Hospital Universitario Marqués de Valdecilla, Spain

^b Grupo Internacional de Ventilación Mecánica, WeVent, Spain

^c Critical Care Unit, Hospital Biprovincial Quillota-Petorca, Chile

* Corresponding author.

Center: Hospital Universitario Marqués de Valdecilla, Dirección del centro: Avda. Valdecilla s/n, 39008 Santander, Spain.

É-mail address: jrodriguez.borregan@scsalud.es (A. González-Castro).

2173-5727/ © 2024 Published by Elsevier Espa?a, S.L.U.

to determine the true prevalence of frailty at the intensive care units (ICU) setting, all patients admitted to these units must be considered.

According to the recent EDEN-12 study,⁵ the chances of hospital admission for patients seen at the ER decrease significantly after 83 years of age, which may also affect ICU admission probability. However, current demographics impose a considerable increase in the population of elderly patients in ICUs of Western societies, and the likelihood of frail patients being admitted to these medical services alone justifies the researchers' interest in evaluating the impact of frailty on the chances of all-cause mortality and other outcomes.⁶

In the last five years, studies conducted with patients admitted to Spanish ICUs^{7,8} have focused on evaluating the prevalence of frailty and its relationship with mortality prediction. We find it interesting to communicate the frailty data referring to a population of 4512 patients who were consecutively admitted to 7 Spanish ICUs from January 2019 through January 2020. The contribution to the sample size from each hospital is shown in Table 1 Appendix A. The study was approved by the ethics committee and a waiver for Informed Consent was granted.

This population was recruited in the context of an external validation study of a mortality score,⁹ and all patients were assessed for the presence of frailty defined according

DOI of refers to article: https://doi.org/10.1016/j.medin.2024 .06.003